Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Dose-Escalation Trial of GEN3013 (epcoritamab) in Relapsed/Refractory B-cell Lymphoma
2017-001748-36Phase 2Unknown
- Sponsor
- Genmab
- Start
- Dec 2017
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epcoritamab in mature B-cell lymphoma, sponsored by Genmab. Primary endpoint: Escalation Phase Primary Endpoints. Status: unknown.
02
Drugs
epcoritamab
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2017-001748-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001748-36.